Arcus Biosciences develops combination therapies using differentiated small molecules and antibodies to enhance treatment efficacy for various cancers. The company focuses on optimizing biologic mechanisms to improve patient outcomes and accelerate the delivery of new cancer therapies through global clinical trials.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCFounders
Product
Problem
Many cancers develop resistance to existing therapies, and the complex interplay of biological mechanisms within the tumor microenvironment often limits the efficacy of single-agent treatments. There is a need for novel therapeutic strategies that can overcome resistance mechanisms and effectively target multiple pathways involved in cancer progression.
Solution
Arcus Biosciences is focused on developing combination therapies designed to enhance treatment efficacy across a range of cancers. The company's approach involves creating differentiated small molecules and antibodies that can be combined to optimize biologic mechanisms and improve patient outcomes. By focusing on specific biologic mechanisms of cancer, Arcus aims to accelerate the development of combination therapies from Phase 1 studies through commercialization. Their pipeline includes clinical candidates targeting TIGIT, the adenosine axis, PD-1, HIF-2⍺, CD39, and AXL. These investigational medicines are being evaluated in multiple clinical trials, both as monotherapies and in combination with other agents, to assess their potential in various cancer types.
Target Audience
Arcus Biosciences primarily targets medical oncologists, clinical researchers, and patients with various types of cancer who may benefit from novel combination therapies.
Features
- Development of differentiated small molecules and antibodies designed for combination therapy
- Focus on optimizing biologic mechanisms of cancer to enhance treatment efficacy
- Clinical trials evaluating novel combinations of investigational medicines
- Pipeline includes clinical candidates targeting TIGIT (domvanalimab), adenosine axis (etrumadenant and quemliclustat), PD-1 (zimberelimab), HIF-2⍺ (casdatifan), CD39 (AB598), and AXL (AB801)
- Clinical collaborations with other pharmaceutical companies to evaluate novel combinations
- Clinical trials cover multiple cancer types, including lung, kidney, gastrointestinal, pancreatic, and colorectal cancers
- Investigational therapies are in Phase 1, Phase 2, and Phase 3 clinical trials